# US Organ on chip Market

> US Organ-on-Chip Market Research Report: Size, Share, Trend Analysis By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Applications (Drug Discovery, Toxicology Research, Others) and By End-User (Pharmaceutical Companies, Research Organizations, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.55%
- **2024:** $ 98.56 Million
- **2025:** $ 102.06 Million
- **2035:** $ 144.68 Million
- **Key Players:** Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissot (FR)

**Report ID:** MRFR/HC/13093-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-organ-on-chip-market-14620

---

## Market Summary

## **US Organ-on-Chip Market Overview**

As per MRFR analysis, the US Organ-on-Chip Market Size was estimated at 16.5 (USD Million) in 2023. The US Organ-on-Chip Market Industry is expected to grow from 18.43 (USD Million) in 2024 to 111.09 (USD Million) by 2035. The US Organ-on-Chip Market CAGR (growth rate) is expected to be around 17.737% during the forecast period (2025 - 2035).

### **Key US Organ-on-Chip Market Trends Highlighted**

The US Organ-on-Chip Market is witnessing significant trends shaped by advancements in biotechnology and regulatory support. Key market drivers include the growing demand for more efficient drug development processes and the reduction of animal testing in research, aligning with ethical considerations and policies from organizations like the FDA that encourage alternative methods.

Researchers are increasingly adopting [organ-on-chip](../../../reports/organ-on-chip-market-8498) technology for its ability to mimic human physiology, leading to faster and more effective drug screening and toxicity testing. Opportunities in this market are emerging due to the increasing collaboration between academic institutions and biotechnology firms in the United States.

This partnership is fostering innovation and addressing specific healthcare needs, such as personalized medicine and tailored drug therapies. As universities and research facilities continue to develop sophisticated organ-on-chip models, it opens the door for new applications in regenerative medicine and disease modeling, leading to further investment and interest in this technology.

Recent trends highlight a growing acceptance of organ-on-chip systems by regulatory bodies in the US, which is crucial for their integration into the broader biomedical research landscape. There is also an increasing focus on developing multi-organ systems that can provide a more comprehensive understanding of human biology and drug responses.

Furthermore, advancements in microengineering and materials science are enhancing the capabilities of organ-on-chip devices, making them more accessible for various applications in pharmaceutical research and toxicology. As these trends continue to evolve, the US organ-on-chip market is poised for significant growth and innovation in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Organ-on-Chip Market Drivers**

### **Increase in Pharmaceutical Research and Development Activities**

The surge in pharmaceutical Research and Development (R&D) activities in the United States is a significant driver for the US Organ-on-Chip Market Industry. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that the pharmaceutical industry invested over 83 billion USD annually in R&D as of 2021.

With the increasing complexity of drug development and the need for more predictive preclinical models, pharmaceutical companies are increasingly adopting Organ-on-Chip technology. This technology allows for more accurate human-relevant data, reducing the time and cost associated with clinical trials.

Noteworthy organizations like Johnson & Johnson and Pfizer are heavily investing in Organ-on-Chip systems to enhance their drug discovery processes, significantly contributing to the growth of this market. Additionally, the Food and Drug Administration (FDA) has begun to recognize the importance of such technologies in regulatory decision-making, which further propels market adoption.

As the US pharmaceutical market continues to showcase robust growth, driven by innovation and technology, the US Organ-on-Chip Market Industry is expected to expand substantially in line with these R&D investments and advancements in regulatory acceptance.

### **Rising Demand for Personalized Medicine**

The increasing emphasis on personalized medicine in the United States is another critical driver influencing the US Organ-on-Chip Market Industry. According to the American Society of Clinical Oncology (ASCO), approximately 50% of all cancer treatments are now tailored to individual genetic markers.

This rise in personalized approaches necessitates the use of Organ-on-Chip systems to develop patient-specific models for drug testing and evaluation. The integration of microfluidic technology in these systems allows researchers to mimic the physiology of individual patients, enabling better customization of therapies.

Established organizations such as Amgen are actively investing in advanced Organ-on-Chip research to support personalized treatment paradigms. With the US healthcare system gradually shifting towards precision medicine, the growing demand for such adaptable and precise models will likely bolster the Organ-on-Chip market significantly.

### **Government Initiatives Supporting Advanced Biotechnologies**

The United States government has been proactive in supporting advancements in biomedical technologies, which is a vital factor aiding the US Organ-on-Chip Market Industry's growth. The National Institutes of Health (NIH) has announced funding initiatives exceeding 1 billion USD toward biomedical innovations that streamline drug testing processes and improve clinical outcomes.

These investments include grant programs specifically aimed at fostering the development of Organ-on-Chip technologies, encouraging universities, and startups to innovate. Organizations like the National Cancer Institute are collaborating with private sector companies to integrate organ-on-chip studies into their existing research frameworks.

This governmental backing not only legitimizes the significance of Organ-on-Chip technology but also fosters a supportive ecosystem that propels industry growth, influencing the integration of such advancements in clinical and research settings.

## **US Organ-on-Chip Market Segment Insights**

### **Organ-on-Chip Market Organ Type Insights**

The US Organ-on-Chip Market is gaining significant traction, driven by innovations in biomedical engineering and the urgent need for more effective drug development and testing platforms. The Organ Type segment includes crucial models such as the Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, and Human-on-Chip, each playing a pivotal role in advancing research and development across various healthcare applications.

The Lung-on-Chip mimics human lung physiology, providing an invaluable tool for studying respiratory diseases and drug responses, reflecting the critical nature of respiratory health in the United States, where chronic lung diseases significantly impact public health. The Heart-on-Chip model serves as an essential platform to assess cardiac drug safety and efficacy, addressing the growing burden of cardiovascular diseases in the nation.

Liver-on-Chip is particularly significant in the realm of pharmacokinetics, allowing researchers to study drug metabolism and toxicity, which is vital given that liver-related ailments account for a substantial percentage of healthcare costs. The Intestine-on-Chip system offers insights into gastrointestinal disorders and can improve the understanding of gut microbiome interactions with drugs, showcasing the rising focus on personalized medicine and microbiome research.

Kidney-on-Chip technology plays an important role in renal drug toxicity studies and disease modeling, which correlates with the increasing prevalence of kidney disorders among the US population. Lastly, the Human-on-Chip represents the convergence of multiple organ systems, enabling more holistic assessments of therapeutic interventions, which is pivotal for regulatory compliance and patient safety in drug development processes.

This diverse range of organ models significantly enhances the US Organ-on-Chip Market segmentation by providing tailored solutions for drug testing, disease modeling, and personalized medicine, ultimately supporting the need for more effective and ethical alternatives to traditional animal testing methods. The demand for these sophisticated models also aligns with various governmental initiatives aimed at fostering innovative biotechnological advances and improving healthcare outcomes in the United States.

As the landscape shifts towards more organ-specific analytical approaches, the Organ Type segment will likely witness continued growth, positioning itself as a cornerstone in the evolution of precision medicine and biopharmaceutical development. With these advancements at the forefront, the overall market dynamics promise a robust evolution, ultimately enhancing the efficiency and effectiveness of the healthcare system in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Organ-on-Chip Market Application Insights**

The Application segment of the US Organ-on-Chip Market is gaining attention due to its transformative potential in various fields, particularly Drug Discovery and Toxicology Research. This segment is vital as it offers innovative ways to model human organ systems, enabling researchers to study drug interactions and toxicological responses effectively.

Drug Discovery holds a significant role in the market, as it enhances the efficiency of preclinical testing by reducing reliance on traditional animal models, thereby aligning with a growing demand for ethical and more predictive approaches in pharmaceuticals. Toxicology Research also plays an important role, allowing for safer and more precise evaluations of chemical exposures and their effects on human health.

As the industry shifts towards personalized medicine, these applications facilitate tailored therapies and quicker drug approvals, addressing both market growth and regulatory demands. The US is at the forefront of such innovations, supported by various initiatives aimed at advancing biomedical research and improving healthcare outcomes. Overall, the Application segment is expected to continue developing as critical advancements transpire within the US Organ-on-Chip Market.

#### **Organ-on-Chip Market End-User Insights**

The US Organ-on-Chip Market is significantly influenced by its End-User segment, comprising Pharmaceutical Companies, Research Organizations, and others. Pharmaceutical Companies play a crucial role in leveraging organ-on-chip technology for drug development and testing, which enhances the accuracy of preclinical studies and reduces the reliance on animal testing.

This segment's growth is driven by increasing investments in innovative drug delivery systems and a rising emphasis on personalized medicine. Research Organizations are also vital, as they utilize organ-on-chip platforms to explore disease mechanisms and therapeutic responses in a controlled environment, allowing for groundbreaking advancements in the field of biomedicine.

By offering a more human-relevant model for research, they contribute significantly to the overall success of the technology. The presence of regulatory support and funding from various governmental agencies promotes the adoption of organ-on-chip systems in these sectors, leading to a broader market expansion. Meanwhile, other users of this technology, including academia and health institutions, are also becoming essential contributors, exploring various applications and driving further innovation within the US Organ-on-Chip Market landscape.

Key factors such as increased demand for advanced in vitro models and the expansion of healthcare research are driving the overall market growth, making it a dynamic and promising industry segment.

### **US Organ-on-Chip Market Key Players and Competitive Insights**

The US Organ-on-Chip Market has rapidly evolved, reflecting significant advancements in biotechnology and drug development processes. This market focuses on the integration of biological and mechanical systems to create microphysiological models that can mimic human organ functions. These models offer invaluable insights into drug efficacy and toxicity, thereby providing a powerful alternative to traditional testing methods.

With increasing investment from both public and private sectors, the competitive landscape is marked by a diverse array of companies vying for market share and technological superiority, indicating a dynamic and rapidly growing sector. The race for developing more sophisticated and functional organ-on-chip systems has become a key driver of innovation, ultimately enhancing the capabilities of research and development within the pharmaceutical industry and other related sectors.

In the context of the US Organ-on-Chip Market, InSphero has established a formidable presence, particularly known for its expertise in developing 3D cell culture technology that facilitates drug testing and toxicology studies. The company’s pioneering techniques enable researchers to replicate organ functionalities more accurately, thereby enhancing the predictive power of in vitro models.

One of the cardinal strengths of InSphero lies in its customized solutions which cater to both research and commercial applications, effectively bridging the gap between basic research and clinical application. Their collaborative efforts with academic institutions and other biotech firms further underscore their commitment to advancing organ-on-chip technology, positioning them as a leader in this niche market segment.

VitroLabs has carved a niche in the US Organ-on-Chip Market with its innovative approaches to regenerative medicine and organ modeling. Focusing on the development of organ-on-chip systems that mimic complex organ functions, VitroLabs provides key products and services that are particularly advantageous for pharmaceutical research and toxicology assessments.

The company's strengths include advanced bioengineering capabilities and strategic partnerships which bolster its market presence. Notably, VitroLabs has engaged in various collaborations and potential mergers that enhance their research capabilities, all while maintaining a strong commitment to regulatory standards, further establishing confidence in their technology. Their continuous investment in R&D further solidifies their position as a noteworthy competitor in the rapidly evolving organ-on-chip landscape in the United States.

### **Key Companies in the US Organ-on-Chip Market Include**

- **[InSphero](https://insphero.com/technology/akura-organ-on-chip-technology)**
- VitroLabs
- NCardia
- Emulate
- Ascendance Bio
- Hurel Corporation
- Organovo
- CureMetrix
- Mimic Technologies
- Pulmodynamics
- Biomimetic Solutions
- TissUse
- Synlogic
- Tara Biosystems

### **US Organ-on-Chip Market Industry Developments**

The US Organ-on-Chip Market has seen significant developments recently, with companies like Emulate and Organovo making strides in their respective technologies to better mimic human organ functions for drug testing and disease modeling. In addition, InSphero has been advancing its 3D tissue models, enhancing the capabilities of Organ-on-Chip applications in pharmaceutical research.

Critical partnerships have formed, such as between Mimic Technologies and industry leaders to expand their product offerings in tissue engineering solutions. As of September 2023, a merger was publicly announced involving Hurel Corporation and Naefin Technologies, aimed at enhancing their organ-on-chip systems to improve drug screening accuracy, which was positively viewed by investors.

Market valuations in the Organ-on-Chip sector reflect a robust growth trajectory, driven by increasing adoption in Research and Development sectors, with many companies reporting accelerated revenue growth in recent quarters. Additionally, TissUse’s expansion into new markets has further solidified its position in the organ-on-chip space, supporting the overall industry momentum.

### **US Organ-on-Chip Market Segmentation Insights**

#### **Organ-on-Chip Market Organ Type Outlook**

- Lung-on-Chip
- Heart-on-Chip
- Liver-on-Chip
- Intestine-on-Chip
- Kidney-on-Chip
- Human-on-Chip

#### **Organ-on-Chip Market Application Outlook**

- Drug Discovery
- Toxicology Research
- Others

#### **Organ-on-Chip Market End-User Outlook**

- Pharmaceutical Companies
- Research Organizations
- Others

## Market Drivers

### Rising Demand for Personalized Medicine

The organ on-chip market is experiencing a notable surge in demand for personalized medicine, driven by the need for tailored therapeutic solutions. As healthcare shifts towards individualized treatment plans, organ-on-chip technologies offer a promising avenue for drug testing and disease modeling. This market segment is projected to grow at a CAGR of approximately 25% from 2025 to 2030, reflecting the increasing interest in precision medicine. The ability to simulate human organ responses in vitro allows for more accurate predictions of drug efficacy and safety, thereby reducing the reliance on animal testing. Consequently, the organ on-chip market is positioned to play a pivotal role in the development of personalized therapies, aligning with the broader trend of patient-centric healthcare.

### Growing Focus on Reducing Animal Testing

The organ on-chip market is significantly influenced by the growing emphasis on reducing animal testing in research and development. Regulatory bodies and ethical considerations are pushing for alternatives that can provide reliable data without the ethical dilemmas associated with animal experimentation. The organ-on-chip technology offers a viable solution by providing human-relevant data that can predict drug responses more accurately. In 2025, it is estimated that the market for alternatives to animal testing will reach $3 billion, highlighting the potential for organ-on-chip systems to capture a substantial share of this market. This shift not only aligns with ethical standards but also enhances the organ on-chip market by promoting innovative testing methods.

### Increased Investment in Biotech Research

Investment in biotechnology research is a significant driver for the organ on-chip market. With funding from both public and private sectors, research institutions are increasingly adopting organ-on-chip technologies to enhance drug discovery and development processes. In 2025, the US biotech sector is expected to receive over $50 billion in investments, with a substantial portion allocated to innovative technologies like organ-on-chip systems. These investments facilitate the advancement of sophisticated models that mimic human physiology, thereby improving the accuracy of preclinical testing. As a result, the organ on-chip market is likely to benefit from this influx of capital, fostering innovation and accelerating the commercialization of new therapeutic solutions.

### Emerging Applications in Drug Development

The organ on-chip market is witnessing a rise in emerging applications within drug development, which is reshaping the landscape of pharmaceutical research. These systems are being utilized for high-throughput screening, toxicity testing, and disease modeling, offering a more efficient alternative to traditional methods. In 2025, the market for drug development technologies is expected to exceed $40 billion, with organ-on-chip systems capturing a growing share due to their ability to provide real-time data on drug interactions. This trend indicates a shift towards more efficient and effective drug development processes, positioning the organ on-chip market as a critical player in the future of pharmaceutical innovation.

### Advancements in Microfabrication Techniques

Advancements in microfabrication techniques are propelling the organ on-chip market forward. These innovations enable the creation of more complex and functional organ models that closely replicate human organ systems. Techniques such as 3D printing and soft lithography are being utilized to develop organ-on-chip devices with enhanced capabilities. As of 2025, the market for microfabrication technologies is projected to grow by 20%, indicating a robust interest in developing sophisticated organ-on-chip systems. This progress allows researchers to create multi-organ systems that can simulate interactions between different organ types, thereby providing a more comprehensive understanding of human biology. Consequently, the organ on-chip market stands to gain from these technological advancements, enhancing its relevance in biomedical research.

## Future Outlook

The [Organ on chip Market](https://www.marketresearchfuture.com/reports/organ-on-chip-market-8498) is projected to grow at a 3.55% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

**New opportunities:**

- Development of customizable organ-on-chip platforms for specific disease models. Partnerships with pharmaceutical companies for drug testing applications. Integration of AI for predictive analytics in organ-on-chip systems.

By 2035, the organ on-chip market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Organ Type: Lung-on-Chip (Largest) vs. Heart-on-Chip (Fastest-Growing)

In the US organ on-chip market, Lung-on-Chip holds the largest market share, attributed to its extensive applications in drug testing and disease modeling. Other segments like Heart-on-Chip and Liver-on-Chip also contribute significantly to the market, but they lag behind in terms of overall share collected from researchers and pharmaceutical companies. Fast-growing technologies, particularly Heart-on-Chip, are receiving substantial investments due to their capability to replicate human heart functions. The increasing demand for personalized medicine and the need for more efficient drug discovery processes are propelling growth in this segment. As regulatory environments shift towards advanced testing methods, these organ-on-chip technologies are positioned for robust growth in the foreseeable future.

Lung-on-Chip (Dominant) vs. Heart-on-Chip (Emerging)

Lung-on-Chip technology is at the forefront of the US organ on-chip market, dominating due to its ability to mimic human lung physiology. This makes it invaluable for studying respiratory diseases and testing inhaled drugs, leading to widespread adoption across research institutions and pharmaceutical companies. Meanwhile, Heart-on-Chip, while emerging, demonstrates rapid growth reflecting significant advancements in bioengineering. Its structure allows for precise simulation of heart functions, making it an essential tool for cardiovascular research. The contrast between these two segments showcases the importance of lung health in medical research, while also highlighting the burgeoning potential of heart models as drug discovery tools.

### By Application: Drug Discovery (Largest) vs. Toxicology Research (Fastest-Growing)

In the US organ on-chip market, Drug Discovery stands out as the largest segment, capturing a significant portion of market share due to its crucial role in developing new therapeutics and personalized medicine approaches. Toxicology Research, on the other hand, has been gaining traction, representing one of the fastest-growing segments as regulatory agencies increasingly push for advanced toxicity assessment methods to replace traditional animal testing. Growth trends in this segment are driven by the necessity for more efficient drug development processes and the demand for innovative toxicity testing solutions. Advancements in organ-on-chip technologies are enabling researchers to create more accurate biological models, which can lead to faster results and reduced costs. This shift towards more humane and effective testing methods, along with increased investments in research and development, is expected to further elevate the growth prospects of these segments.

Drug Discovery (Dominant) vs. Toxicology Research (Emerging)

The Drug Discovery segment within the US organ on-chip market is characterized by its dominant position as a key driver for innovation and development in pharmaceuticals. It enables researchers to streamline the drug development process, allowing for better understanding of drug interactions on human tissues without conventional testing methods. In contrast, the Toxicology Research segment is emerging rapidly, focusing on the evaluation of drug safety and potential side effects, reflecting a shift towards more ethical research practices. Both segments are critical, but Drug Discovery currently leads due to its broader applications in therapeutic development. Toxicology Research is becoming increasingly relevant as it addresses regulatory pressures and societal demand for more reliable and humane testing alternatives, making it a pivotal area for future growth.

### By End-User: Pharmaceutical Companies (Largest) vs. Research Organizations (Fastest-Growing)

In the US organ on-chip market, pharmaceutical companies are currently the largest end-user segment, commanding a significant share due to their adoption of organ on-chip technologies for drug development and testing. Meanwhile, research organizations are emerging robustly, capturing an increasing market presence as they explore innovative applications of organ-on-chip systems for their projects, indicating a healthy interest in and investment towards advanced research methodologies. The growth trends within this segment are powered by a heightened focus on personalized medicine and the need for more accurate preclinical testing models. Pharmaceutical companies are leveraging these technologies to improve the efficiency of drug discovery, while research organizations are rapidly advancing their efforts to unveil new therapeutic strategies, enhancing their demand for organ on-chip solutions as a vital tool for experimentation and development.

Pharmaceutical Companies (Dominant) vs. Research Organizations (Emerging)

Pharmaceutical companies represent the dominant force in the US organ on-chip market, utilizing these platforms to enhance drug testing and approval processes. Their substantial investment in R&D and the integration of these technologies into their operations underscore their critical role in the market. Conversely, research organizations, identified as an emerging segment, are expanding their footprint by utilizing organ-on-chip models for a range of studies, from disease modeling to toxicity testing. This diversification within research applications facilitates their rapid growth, driven by increased funding and collaborative projects aimed at technological advancement in biomedicine. Both segments are pivotal to the evolution of organ on-chip technologies, each contributing uniquely to the market's overall dynamics.

## Competitive Benchmarking

The organ on-chip market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations. Key growth drivers include the increasing demand for advanced drug testing methods, personalized medicine, and the need for more ethical research alternatives. Major players such as Emulate (US), Organovo (US), and Hesperos (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Emulate (US) focuses on expanding its product offerings and enhancing its technology through partnerships, while Organovo (US) emphasizes its proprietary bioprinting technology to create functional human tissues. Hesperos (US) is leveraging its expertise in multi-organ systems to cater to the growing interest in complex biological models, thereby shaping a competitive environment that prioritizes innovation and technological advancement.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation allows for diverse approaches to product development and customer engagement, as companies seek to differentiate themselves through unique offerings and specialized services. The collective influence of these key players fosters a competitive atmosphere that encourages continuous improvement and adaptation to market demands.
In October Emulate (US) announced a strategic partnership with a leading pharmaceutical company to develop organ-on-chip models tailored for specific drug testing applications. This collaboration is likely to enhance Emulate's credibility and expand its reach within the pharmaceutical sector, potentially leading to increased revenue streams and market penetration. The partnership underscores the importance of aligning with industry leaders to drive innovation and meet the evolving needs of drug development.
In September Organovo (US) launched a new line of bioprinted liver tissues designed for toxicity testing. This product introduction is significant as it addresses a critical gap in the market for reliable and predictive models for liver function. By enhancing its product portfolio, Organovo (US) positions itself as a leader in the bioprinting space, potentially attracting new clients and partnerships in the pharmaceutical and biotechnology sectors.
In August Hesperos (US) secured a grant to develop a multi-organ-on-chip platform aimed at studying complex disease interactions. This funding is pivotal as it not only validates Hesperos's innovative approach but also provides the necessary resources to advance its research and development efforts. The ability to study multiple organ interactions could lead to breakthroughs in understanding disease mechanisms, thereby enhancing Hesperos's competitive edge in the market.
As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into organ-on-chip technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding their capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver customized solutions. This shift may redefine market dynamics, emphasizing the importance of agility and responsiveness to emerging trends.

## Recent News & Developments

The US Organ-on-Chip Market has seen significant developments recently, with companies like Emulate and Organovo making strides in their respective technologies to better mimic human organ functions for drug testing and disease modeling. In addition, InSphero has been advancing its 3D tissue models, enhancing the capabilities of Organ-on-Chip applications in pharmaceutical research.

Critical partnerships have formed, such as between Mimic Technologies and industry leaders to expand their product offerings in tissue engineering solutions. As of September 2023, a merger was publicly announced involving Hurel Corporation and Naefin Technologies, aimed at enhancing their organ-on-chip systems to improve drug screening accuracy, which was positively viewed by investors.

Market valuations in the Organ-on-Chip sector reflect a robust growth trajectory, driven by increasing adoption in Research and Development sectors, with many companies reporting accelerated revenue growth in recent quarters. Additionally, TissUse’s expansion into new markets has further solidified its position in the organ-on-chip space, supporting the overall industry momentum.

## Report Scope

| MARKET SIZE 2024 | 98.56(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 102.06(USD Million) |
| MARKET SIZE 2035 | 144.68(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.55% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Emulate (US), TissUse (DE), Mimetas (NL), Organovo (US), Synlogic (US), Hesperos (US), InSphero (CH), Reinnervate (GB), Tissot (FR) |
| Segments Covered | Organ Type, Application, End-User |
| Key Market Opportunities | Advancements in organ-on-chip technology enhance drug testing efficiency and reduce reliance on animal models. |
| Key Market Dynamics | Technological advancements drive innovation in organ on-chip systems, enhancing drug testing and personalized medicine applications. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US organ on-chip market?**
A: The market valuation was $98.56 Million in 2024.

**Q: What is the projected market valuation for the US organ on-chip market by 2035?**
A: The projected valuation for 2035 is $144.68 Million.

**Q: What is the expected CAGR for the US organ on-chip market during the forecast period 2025 - 2035?**
A: The expected CAGR is 3.55% during the forecast period.

**Q: Which organ-on-chip segments are expected to show significant growth?**
A: Segments like Liver-on-Chip and Lung-on-Chip are projected to grow, with valuations of $28.0 Million and $22.0 Million respectively.

**Q: Who are the key players in the US organ on-chip market?**
A: Key players include Emulate, Organovo, and Synlogic among others.

**Q: What applications are driving the demand for organ-on-chip technologies?**
A: Drug Discovery and Toxicology Research are primary applications, with valuations of $58.0 Million and $42.0 Million respectively.

**Q: What are the end-user segments in the US organ on-chip market?**
A: End-users include Pharmaceutical Companies and Research Organizations, with valuations of $57.0 Million and $42.0 Million respectively.

**Q: How does the market for organ-on-chip technologies compare across different organ types?**
A: Liver-on-Chip leads with a valuation of $28.0 Million, followed by Lung-on-Chip at $22.0 Million.

**Q: What is the potential impact of organ-on-chip technologies on drug development?**
A: These technologies may enhance drug development efficiency, particularly in Drug Discovery applications.

**Q: How are organ-on-chip technologies expected to evolve by 2035?**
A: The market is likely to expand, driven by advancements in technology and increasing applications in research.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-organ-on-chip-market-14620*